122 related articles for article (PubMed ID: 1378692)
1. Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost.
Buerke M; Dieterich HA; Meyer J; Darius H
Agents Actions Suppl; 1992; 37():71-7. PubMed ID: 1378692
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro.
Buerke M; Cyrus T; Darius H
Thromb Res; 1997 Oct; 88(2):89-98. PubMed ID: 9361363
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
4. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
5. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
[TBL] [Abstract][Full Text] [Related]
6. Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo.
Spiecker M; Darius H; Meyer J
Thromb Res; 1993 Jun; 70(5):405-15. PubMed ID: 7690993
[TBL] [Abstract][Full Text] [Related]
7. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
Anfossi G; Massucco P; Mularoni E; Cavalot F; Mattiello L; Trovati M
Prostaglandins Leukot Essent Fatty Acids; 1993 Nov; 49(5):839-45. PubMed ID: 7508131
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
Azuma H; Takashima Y; Ishikawa M; Yamakado T
Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
10. Mode of action of 2-(diethylamino)-7-ethoxychromone on human platelets.
Leoncini G; Maresca M; Colao C; Buzzi E; Mazzei M
Cell Biochem Funct; 1991 Apr; 9(2):79-85. PubMed ID: 1718622
[TBL] [Abstract][Full Text] [Related]
11. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.
Seiler SM; Brassard CL; Federici ME; Romine J; Meanwell NA
Prostaglandins; 1997 Jan; 53(1):21-35. PubMed ID: 9068064
[TBL] [Abstract][Full Text] [Related]
12. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels.
Lindgren SH; Andersson TL; Vinge E; Andersson KE
Acta Physiol Scand; 1990 Oct; 140(2):209-19. PubMed ID: 2176433
[TBL] [Abstract][Full Text] [Related]
13. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
Gray SJ; Heptinstall S
Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
[TBL] [Abstract][Full Text] [Related]
14. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
Simpson AW; Reeves ML; Rink TJ
Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
[TBL] [Abstract][Full Text] [Related]
15. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors.
Seiler S; Brassard CL; Federici ME
Prostaglandins; 1990 Aug; 40(2):119-30. PubMed ID: 2171039
[TBL] [Abstract][Full Text] [Related]
16. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human platelets and polymorphonuclear neutrophils by the potent and metabolically stable prostaglandin D2 analog ZK 118.182.
Darius H; Michael-Hepp J; Thierauch KH; Fisch A
Eur J Pharmacol; 1994 Jun; 258(3):207-13. PubMed ID: 7522176
[TBL] [Abstract][Full Text] [Related]
18. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function.
Murray KJ; Eden RJ; Dolan JS; Grimsditch DC; Stutchbury CA; Patel B; Knowles A; Worby A; Lynham JA; Coates WJ
Br J Pharmacol; 1992 Oct; 107(2):463-70. PubMed ID: 1422592
[TBL] [Abstract][Full Text] [Related]
19. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
[TBL] [Abstract][Full Text] [Related]
20. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.
Murray KJ; England PJ; Hallam TJ; Maguire J; Moores K; Reeves ML; Simpson AW; Rink TJ
Br J Pharmacol; 1990 Mar; 99(3):612-6. PubMed ID: 2158847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
